Reata Pharmaceuticals Inc (NASDAQ:RETA) Given Consensus Rating of “Strong Buy” by Brokerages
Reata Pharmaceuticals Inc (NASDAQ:RETA) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $33.00 for the company and are anticipating that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also given Reata Pharmaceuticals an industry rank of 92 out of 265 based on the ratings given to its competitors.
Several equities analysts recently weighed in on RETA shares. Cowen and Company started coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They set an “outperform” rating and a $22.00 target price on the stock. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Cos. assumed coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, Citigroup Inc. assumed coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They issued a “buy” rating and a $32.00 price objective on the stock.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) traded down 6.4223% during trading on Tuesday, hitting $28.1201. The company’s stock had a trading volume of 100,158 shares. The firm’s 50 day moving average price is $19.96 and its 200-day moving average price is $19.13. Reata Pharmaceuticals has a 52 week low of $11.03 and a 52 week high of $32.22. The company’s market cap is $627.78 million.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Thursday, August 11th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The business had revenue of $12.40 million for the quarter. On average, analysts predict that Reata Pharmaceuticals will post ($0.54) earnings per share for the current year.
In related news, major shareholder James W. Traweek, Jr. bought 164,600 shares of the company’s stock in a transaction dated Thursday, June 30th. The stock was bought at an average price of $19.78 per share, with a total value of $3,255,788.00. Following the transaction, the insider now owns 35 shares of the company’s stock, valued at $692.30. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Cpmg Inc bought 73,403 shares of the company’s stock in a transaction dated Monday, June 27th. The stock was bought at an average cost of $19.26 per share, with a total value of $1,413,741.78. Following the transaction, the director now directly owns 113 shares in the company, valued at approximately $2,176.38. The disclosure for this purchase can be found here.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.